| | Exhibit 99.03 |
Hampshire International Business Park
Chineham Basingstoke
Hampshire RG24 8EP
United Kingdom
Tel +44 (0)1256 894000
Fax +44 (0)1256 894708
www.shire.com |  |
| | |
| Press Release | |
| | |
17 August 2006Shire plc (the “Company”)The Company announces that it was notified on 17 August 2006, in accordance with Sections 198 to 202 of the Companies Act, that, as at 11 August 2006, Barclays PLC, through its associated companies, held a notifiable interest, in aggregate, of 24,775,951 ordinary shares of £0.05p each in the capital of the Company. These holdings represent 4.96% per cent of the issued ordinary share capital of the Company.
T MayCompany SecretaryFor further information please contact:| | | |
| Investor Relations | Cléa Rosenfeld (Rest of the World) | +44 1256 894 160 |
| Brian Piper (North America) | +1 484 595 8252 |
Notes to editorsSHIRE PLCShire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.
Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
For further information on Shire, please visit the Company’s website:www.shire.com.
